Insulet Corp. (PODD) Sets New 12-Month High at $44.43
Insulet Corp. (NASDAQ:PODD) hit a new 52-week high during trading on Monday . The company traded as high as $44.43 and last traded at $44.42, with a volume of 179,902 shares changing hands. The stock had previously closed at $42.99.
PODD has been the topic of a number of recent analyst reports. Zacks Investment Research downgraded shares of Insulet Corp. from a “hold” rating to a “sell” rating in a research report on Thursday, April 28th. William Blair raised shares of Insulet Corp. from a “market perform” rating to an “outperform” rating in a research report on Friday, April 29th. Canaccord Genuity reaffirmed a “hold” rating on shares of Insulet Corp. in a research report on Saturday, April 30th. Sterne Agee CRT reaffirmed a “neutral” rating on shares of Insulet Corp. in a research report on Monday, May 16th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $44.00 target price on shares of Insulet Corp. in a research report on Friday, May 20th. Six research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $40.92.
The stock’s market capitalization is $2.55 billion. The company has a 50 day moving average of $34.82 and a 200-day moving average of $31.83.
Insulet Corp. (NASDAQ:PODD) last posted its earnings results on Wednesday, August 3rd. The company reported ($0.08) EPS for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.09. During the same period in the previous year, the firm posted ($0.30) earnings per share. The firm had revenue of $87.30 million for the quarter, compared to analyst estimates of $81.10 million. The company’s revenue for the quarter was up 44.2% on a year-over-year basis. On average, equities analysts expect that Insulet Corp. will post ($0.44) earnings per share for the current fiscal year.
In related news, CEO Patrick J. Sullivan purchased 45,000 shares of the company’s stock in a transaction that occurred on Wednesday, May 18th. The stock was acquired at an average price of $27.00 per share, for a total transaction of $1,215,000.00. Following the completion of the purchase, the chief executive officer now owns 202,795 shares in the company, valued at $5,475,465. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Regina O. Sommer sold 8,019 shares of Insulet Corp. stock in a transaction on Wednesday, May 25th. The stock was sold at an average price of $30.42, for a total transaction of $243,937.98. Following the completion of the sale, the director now owns 20,330 shares of the company’s stock, valued at approximately $618,438.60. The disclosure for this sale can be found here.
Several hedge funds recently modified their holdings of the company. New York State Common Retirement Fund raised its stake in shares of Insulet Corp. by 3.2% in the fourth quarter. New York State Common Retirement Fund now owns 85,940 shares of the company’s stock worth $3,249,000 after buying an additional 2,700 shares during the period. California Public Employees Retirement System raised its stake in shares of Insulet Corp. by 16.8% in the fourth quarter. California Public Employees Retirement System now owns 91,700 shares of the company’s stock worth $3,467,000 after buying an additional 13,200 shares during the period. Finally, Morgan Stanley raised its stake in shares of Insulet Corp. by 12.0% in the fourth quarter. Morgan Stanley now owns 766,245 shares of the company’s stock worth $28,971,000 after buying an additional 82,302 shares during the period.
Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The OmniPod System consists of the OmniPod, a small, self-adhesive disposable tubeless OmniPod device, which is worn on the body for approximately three days at a time and its wireless handheld Personal Diabetes Manager (PDM).
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.